| Patient | Sun Yat-sen |
|---|---|
| Date of birth | 1866-11-12 |
| Identifiers | MRN HR-ET016-SYN-TD; SSN (made up) 000-16-4183 |
| Document date | 1924-08-03 |
| Author | Wen-Li Huang, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Before cycle 4: restaging CT, tumor marker, side effects, and genomic profiling result. [S]
Mr. Sun returns before cycle 4, nine weeks after starting treatment. He has had all three cycles on schedule. He is nauseated on the two days after each infusion, which ondansetron controls, and tired for three or four days after each day-8 dose; otherwise he works most days. He has no diarrhea, rash, cough or breathlessness, no numbness or tingling, and no ringing in the ears or change in hearing. The ache under his ribs is 1 to 2 of 10 and he takes acetaminophen only a few times a week. He has seen the palliative care team twice and says it helped him sleep and think about his priorities. The restaging CT four days ago and the HBV DNA drawn with it are back, and so is the genomic profiling of his tumor. [S]
| Element | Detail |
|---|---|
| Cycles | Three, all on schedule |
| Side effects | Nausea two days after infusions, controlled; tiredness after day-8 doses |
| Immune-related symptoms | None |
| Pain | 1 to 2 of 10; acetaminophen a few times a week |
| Palliative care | Two visits; sleep and coping better |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired after day-8 doses; weight 59.2 kg; no fever |
| Gastrointestinal | Positive | Nausea for two days after infusions; no diarrhea or jaundice |
| Ears, nose, mouth, and throat | Negative | No tinnitus or hearing change; no mouth sores |
| Respiratory | Negative | No cough or breathlessness |
| Integumentary | Negative | No rash or itching |
| Neurological | Negative | No numbness or tingling |
| Psychiatric | Negative | Mood steadier; sleeping better; PHQ-9 5 |
7 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Acetaminophen 500 mg oral tablet, two tablets by mouth every 8 hours as needed for right upper abdominal ache; no more than 3,000 mg a day | Two tablets by mouth every 8 hours as needed, no more than 3,000 mg a day | Oral route | 1924-05-04 | active | S |
| Gemcitabine 1,000 mg/m2 (1,660 mg) intravenous infusion on days 1 and 8 of each 21-day cycle | Days 1 and 8 of each 21-day cycle, up to 8 cycles | Intravenous route | 1924-06-01 | active | S |
| Cisplatin 25 mg/m2 (41 mg) intravenous infusion on days 1 and 8 of each 21-day cycle | Days 1 and 8 of each 21-day cycle, up to 8 cycles, with hydration | Intravenous route | 1924-06-01 | active | S |
| Durvalumab 1,500 mg intravenous infusion on day 1 of each 21-day cycle | Day 1 of each 21-day cycle with chemotherapy, then every 4 weeks alone | Intravenous route | 1924-06-01 | active | S |
| Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nausea | One tablet by mouth every 8 hours as needed for nausea | Oral route | 1924-06-01 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1924-08-03 | Body height | 165 | cm | S |
| 1924-08-03 | Body weight | 59.2 | kg | S |
| 1924-08-03 | Body mass index (BMI) [Ratio] | 21.7 | kg/m2 | S |
| 1924-08-03 | Systolic blood pressure | 122 | mm[Hg] | S |
| 1924-08-03 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 1924-08-03 | Heart rate | 82 | /min | S |
| 1924-08-03 | Respiratory rate | 16 | /min | S |
| 1924-08-03 | Body temperature | 36.6 | Cel | S |
| 1924-08-03 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1924-08-03 | Leukocytes [#/volume] in Blood by Automated count | 4.6 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1924-08-03 | Neutrophils [#/volume] in Blood by Automated count | 2.4 | 10*3/uL | 1.8-7.7 10*3/uL | Normal | S |
| 1924-08-03 | Hemoglobin [Mass/volume] in Blood | 10.9 | g/dL | 13.2-17.1 g/dL | Low | S |
| 1924-08-03 | Platelets [#/volume] in Blood by Automated count | 188 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1924-08-03 | Sodium [Moles/volume] in Serum or Plasma | 136 | mmol/L | 135-145 mmol/L | Normal | S |
| 1924-08-03 | Potassium [Moles/volume] in Serum or Plasma | 4 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1924-08-03 | Creatinine [Mass/volume] in Serum or Plasma | 0.92 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 1924-08-03 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1919)/1.73 sq M | 97 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1924-08-03 | Glucose [Mass/volume] in Serum or Plasma | 94 | mg/dL | 70-99 mg/dL | Normal | S |
| 1924-08-03 | Magnesium [Mass/volume] in Serum or Plasma | 1.7 | mg/dL | 1.7-2.2 mg/dL | Normal | S |
| 1924-08-03 | Albumin [Mass/volume] in Serum or Plasma | 3.6 | g/dL | 3.5-5 g/dL | Normal | S |
| 1924-08-03 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.7 | mg/dL | 0.2-1.2 mg/dL | Normal | S |
| 1924-08-03 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 158 | U/L | 40-129 U/L | High | S |
| 1924-08-03 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 34 | U/L | 10-40 U/L | Normal | S |
| 1924-08-03 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 30 | U/L | 7-55 U/L | Normal | S |
| 1924-08-03 | Thyrotropin [Units/volume] in Serum or Plasma | 2.4 | m[IU]/L | 0.45-4.5 mIU/L | Normal | S |
| 1924-08-03 | Cancer Ag 19-9 [Units/volume] in Serum or Plasma | 168 | U/mL | <=35 U/mL | High | S |
| 1924-08-03 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 5 | {score} | S | ||
| 1924-08-03 | ECOG Performance Status score | 1 | {score} | S |
Vital signs recorded on 1924-08-03; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Thin, well; blood pressure 122/78, pulse 82; weight 59.2 kg; no jaundice |
| Abdomen | Liver edge firm, 3 cm below the right costal margin, smaller than at diagnosis; no ascites |
| Skin | No rash; port site clean |
| Neurological | Light touch and vibration normal in the fingers and toes |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Right upper quadrant abdominal mass with weight loss: a dull ache under the right ribs and early fullness for about three months, 4 kg weight loss, and a firm, non-tender mass felt 4 cm below the right costal margin; no jaundice, fever, or itching. Ultrasound today: a 6.8 cm solid, heterogeneous mass in liver segments IV and V that cannot be separated from the gallbladder, which contains stones; the rest of the liver is smooth, with no ascites. Multiphase CT, tumor markers, hepatitis serology and medical oncology consultation arranged | resolved | confirmed | R19.01 | S — Synthetic presenting problem anchored to the documented right upper abdominal mass; superseded by the biopsy diagnosis. |
| Adenocarcinoma of the gallbladder invading the liver: core biopsy of the liver mass shows moderately differentiated adenocarcinoma (CK7 positive, CK20 and CDX2 negative), and multiphase CT and MRI show a 7.1 cm mass arising from the gallbladder fundus and invading liver segments IVb and V, with gallstones and two enlarged nodes in the hepatoduodenal ligament; no cirrhosis; alpha-fetoprotein normal, CA 19-9 raised. Clinical T3 N1 before staging laparoscopy (AJCC 8th edition). Synthetic modern episode linked to his documented final illness, described in life as liver cancer and at autopsy as gallbladder adenocarcinoma | active | confirmed | C23 | S — Synthetic modern diagnosis chosen to fit the documented findings: a mass involving the liver at operation and gallbladder adenocarcinoma at autopsy. |
| Resolved hepatitis B infection: hepatitis B surface antigen negative, total core antibody positive, surface antibody positive, HBV DNA undetectable; hepatitis C antibody negative. At risk of reactivation during chemotherapy and immunotherapy; monitored | active | confirmed | Z86.19 | S — Synthetic serology; not a claim that he had hepatitis B in his lifetime. No fetched source mentions hepatitis. |
| Peritoneal metastases from gallbladder adenocarcinoma: several 3 to 6 mm nodules on the parietal peritoneum and omentum at staging laparoscopy, biopsy positive for adenocarcinoma of the same type; stage IVB (M1), not resectable | active | confirmed | C78.6 | S — Synthetic finding anchored to the peritoneal metastases reported at autopsy. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Imaging | CT of the chest, abdomen and pelvis | At staging, then every 2 to 3 months on treatment | Completed today | Four days ago: mass 5.6 cm from 7.1 cm; nodes and peritoneal nodules smaller; no new lesions; stable disease, sum down 24% |
| Laboratory | CA 19-9 (and CEA when raised) | At diagnosis, then with each cycle or restaging | Completed today | CA 19-9 168 U/mL, from 498 |
| Laboratory | Blood count with neutrophils | Before every dose (days 1 and 8) | Completed today | White cells 4.6, neutrophils 2.4, hemoglobin 10.9 g/dL (grade 1 anemia), platelets 188; adequate for treatment |
| Laboratory | Creatinine and eGFR | Before every dose (days 1 and 8) | Completed today | Creatinine 0.92 mg/dL, eGFR 97 |
| Laboratory | Magnesium and potassium | Before every dose (days 1 and 8) | Completed today | Magnesium 1.7 mg/dL (lower limit), potassium 4.0 mmol/L, sodium 136 mmol/L; dietary magnesium advised |
| Laboratory | Liver tests (bilirubin, alkaline phosphatase, AST, ALT, albumin) | Before every dose (days 1 and 8) | Completed today | Bilirubin 0.7 mg/dL, alkaline phosphatase 158, AST 34, ALT 30 U/L, albumin 3.6 g/dL; improving |
| Laboratory | TSH | Baseline, then every 4 to 6 weeks on durvalumab | Completed today | 2.4 mIU/L |
| Laboratory | Glucose | Baseline, then with each pre-dose chemistry panel on durvalumab | Completed today | 94 mg/dL; on the standing pre-dose order since cycle 1 day 8, after the gap at cycle 1 day 1 |
| Laboratory | HBV DNA and ALT (resolved hepatitis B) | Every 3 months during treatment and for 6 to 12 months after | Completed today | HBV DNA undetectable four days ago; ALT 30 U/L |
| Medication safety | Immune-related side effects (diarrhea, rash, cough or breathlessness, fatigue, endocrine symptoms) | Every visit | Completed today | No diarrhea, rash, cough, breathlessness or endocrine symptoms |
| Medication safety | Chemotherapy side effects: nausea, fatigue, neuropathy, hearing | Every visit | Completed today | Grade 1 nausea and fatigue; no neuropathy |
| Examination | Hearing (cisplatin) | Baseline before cisplatin, then by symptoms each cycle | Completed today | No tinnitus or hearing change; whispered voice heard |
| Survey | ECOG performance status | Every visit | Completed today | ECOG 1 |
| Examination | Weight and nutrition | Every visit | Completed today | 59.2 kg, 0.8 kg below the start of treatment |
| Survey | Pain | Every visit | Completed today | 1 to 2 of 10 |
| Survey | Distress and depression (PHQ-9) | At each change in treatment or status | Completed today | PHQ-9 5 |
| Laboratory | Comprehensive genomic profiling of tumor tissue | At diagnosis of advanced disease | Completed today | No targetable alteration; microsatellite stable |
| Referral | Specialist palliative care | From the diagnosis of advanced cancer | Completed today | Two visits; ongoing every 3 to 4 weeks |
Goal progress:
Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Biliary Tract Cancers (2026); Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer (TOPAZ-1) (2022); Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update (2020); Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update (2017); Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update (2021)
Follow-up: Cycles 4 to 7 as scheduled. Visit before cycle 8 with a restaging CT, HBV DNA and ALT. Next scheduled visit 1924-09-21: periodic adult preventive visit. [S]